| Bioactivity | EGFR kinase inhibitor 4 (Compound 4) is a bivalent ATP-allosteric EGFR inhibitor (IC50: 1.8 nM for mutant EGFR (LRTMCS)). EGFR kinase inhibitor 4 can be used for research of NSCLC[1]. |
| Target | IC50: 1.8 nM for mutant EGFR (LRTMCS) |
| Invitro | EGFR kinase inhibitor 4 (0-10 μM，6 小时) 抑制人 NSCLC 细胞系 (H1975、H3255、HCC827 细胞) 中的 LRTM 磷酸化 (pY1068) 以及下游 pERK 和 pAKT[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> EGFR kinase inhibitor 4 相关抗体: |
| CAS | 2922402-05-7 |
| Formula | C40H34N8O4 |
| Molar Mass | 690.75 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wittlinger F, et al. Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Commun Chem. 2024 Feb 20;7(1):38. |
EGFR kinase inhibitor 4
CAS: 2922402-05-7 F: C40H34N8O4 W: 690.75
EGFR kinase inhibitor 4 (Compound 4) is a bivalent ATP-allosteric EGFR inhibitor (IC50: 1.8 nM for mutant EGFR (LRTMCS))
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.